Skip to main content

Remote Job Finders (RJF)

Thanks, But No Thanks: Biopharmas Hiring Less International Talent

Given today’s available local talent pool, biopharma companies are less likely to turn toward international job candidates, according to a talent acquisition expert. Findings from two recent BioSpace LinkedIn polls underscore the issue.

Sanofi, Gilead Deepen Protein Degrader Pipelines in Separate Deals With Kymera

Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move forward with another protein degrader from the biotech, designed to target immune-mediated diseases.

FDA Churn Continues, RFK Faces Congress, Obesity Insights at ADA, BIO2025 Recap

Robert F. Kennedy Jr. testified in front of largely combative congresspeople on vaccine policy, his MAHA report and more; the mass leadership exodus at the FDA continues as CDER and CBER shed key staff; Kennedy’s revamped CDC vaccine advisors convene for their first meeting; Novo and Lilly present new data at the American Diabetes Association’s annual meeting; and BioSpace recaps BIO2025.
Scroll to top